Campbell Neurosciences / CNSI - Basic Overview w/ links

Post Reply
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Campbell Neurosciences / CNSI - Basic Overview w/ links

Post by trader32176 »

Campbell Neurosciences / CNSI - Basic Overview w/ links


Campbell Neurosciences, Inc.

https://campbellneurosciences.com/

Investment Opportunity
https://campbellneurosciences.com/wp-co ... 0-2021.pdf

Management
https://campbellneurosciences.com/management-2/


Ms. Kalina O’Connor – Chief Executive Officer


Kalina O’Connor is the daughter of Kathleen Campbell, a victim of suicide who the Division Campbell Neurosciences is named after. Kalina is a serial entrepreneur having experience in the area of counselling and biotechnology business development. Kalina worked in various high-end suicide prevention/rehabilitation organizations for a decade, which provided her an intimate understanding of the shortcomings that exist in current approach to brain understanding and reprogramming. Subsequently, Kalina was engaged with biotechnology organizations such as NarcoStem, Therapsol and Bioscientific Holdings, providing introductions to licensing opportunities from academia.

James Veltmeyer, MD – Chief Medical Officer


Dr. Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing 36 doctors.

Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the most prestigious honor awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

Jona Barnes, Chief Financial Officer


Timothy G. Dixon – Chairman


Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. Mr. Dixon has attended hundreds of hours of continuing medical/dental education throughout the years and has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies.

Thomas E.Ichim, Ph.D. – Director


Dr. Ichim was appointed to the Board of Directors on January 22, 2016. Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date, he has published 121 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”

Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr. Ichim is an inventor on 135 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.

Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, an MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D. in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.


8/11/20
Therapeutic Solutions International Launches Campbell Neurosciences Division aimed at Biologically Identifying and Repairing Suicide-Prone Brains
Company Leverages Existing Immunology and Regenerative Medicine Intellectual Property to Attack Second Leading Cause of Death in Young People

https://www.prnewswire.com/news-release ... 10221.html

12/31/20
Therapeutic Solutions International Launches Campbell Neurosciences Inc as First Suicide Focused Regenerative Psychiatry Biotechnology Company
Campbell Neurosciences to License Key Intellectual Property Assets as Clinical Trials of Campbell Score and Kaihani Score are Ongoing

https://www.prnewswire.com/news-release ... 99636.html


Scientific Advisory Board
https://campbellneurosciences.com/management/

Ms. Famela Ramos – Advisor


Famela Ramos is a Nurse, a Researcher, and a Politician. Famela was running for Congress in the 53nd Congressional District. Ms. Ramos came to the United States from the Philippines at the age of two, when her father joined the United States Navy. Her parents worked tirelessly to support the family of 5 children, all of which became successful entrepreneurs and Government Employees. As a nurse, Famela has experience from the beginning of life, having practiced in pediatric nursing, to the end of life, having worked as a hospice nurse. Her excellence in nursing and research is attested by 7 peer reviewed publications that she collaborated with Academy and Industry in advancing cutting edge research in immunology and regenerative medicine.

The first paper, was a collaboration with the Moores Cancer Center and several biotechnology companies, describing the state of the art in cancer immunotherarpy, and proposing future directions. The second paper, discussed the possibility of stimulating regeneration of injured lung stem cells using specific types of laser and light based interventions, this was a collaboration between the University of Utah and the University of California, San Diego. The third paper, a collaboration between a nutraceutical company and Indiana University, demonstrated the beneficial effects of a nutritional supplement on circulating stem cells in healthy volunteers. The fourth publication, was the first successful use of two different types of stem cells in a patient with heart failure, which resulted in a profound improvement. The fifth publication is a report of 114 patients that were treated with umbilical cord blood stem cells and demonstrated safety and signals of efficacy in collaboration with a Chinese Biotech company. The sixth publication was successful treatment of a spinal cord injury patient with stem cells. The seventh publication was the basis for an investigational new drug (IND) application to the FDA, describing use of fat stem cells to treat aplastic anemia.

Ms. Ramos has established the Right to Try Foundation, which assists companies in utilizing this new law that allows for accelerated patient access to experimental medication. Through this Foundation Ms Ramos facilitated the first utilization of a cancer vaccine in the United States, and has been assisting both public and private companies. Most recently the Foundation has collaborated on filing new patents for means of implementing the Right to Try Law. Ms. Ramos is a board member of Silent Voices, a Pregnancy Resource Center that provides counselling to woman in emergency pregnancies, alternatives to abortion, and for woman that do choose abortion, post abortion support. Ms. Ramos has been endorsed by business and community leaders as well as nationally known athletes including Dr. Peter Farrell, founder of Resmed, a $18 billion company, and Wes Chandler, an NFL Hall of Fame San Diego Charger.

Howard J. Leonhardt, Advisor


Howard Leonhardt is an inventor and serial entrepreneur. He has 21 U.S. patents with over 100 patent claims for products for treating cardiovascular disease and has over 40 new patent claims pending. His TALENT (Taheri-Leonhardt) stent graft developed in the early 1990′s holds a leading world market share for repairing aortic aneurysms without surgery.

His inventions have treated over 500,000 patients in 60 countries. In early 1999 Leonhardt founded Bioheart, Inc. www.bioheartinc.com a leader in applying adult muscle stem cells to treat heart failure.. Leonhardt holds a Diploma in International Trade from Anoka Technical College. He attended the University of Minnesota,Anoka Ramsey College and UCLA Extension. He holds an honorary Doctorate in Biomedical Engineering from the University of Northern California and is an honorary alumnus of the University of Florida and Florida International University. He is co-leader of Startup California and Founder and Chairman of The California Stock Exchange TM (Cal-X) preparing to be the first social good impact stock exchange currently operating the Cal-X 30 Social Good Impact fund powered by Motif Investing- www.calstockexchange.com – He founded Cal-X Crowdfund Connect www.calxcrowdfund.com a crowdfunding campaign management co. and Cal-X Stars Business Accelerator, Inc.www.calxstars.com a business incubator and accelerator focused on cardiovascular life sciences and social good impact innovations.

J. Christopher Mizer – Advisor


J. Christopher Mizer founded Vivaris in June of 1998. Vivaris (formerly Lake Erie Capital) invests in and acquires middle-market businesses in a broad range of industries that are leaders in their market niches. Mr. Mizer serves as the chairman of each of the portfolio companies and guides key strategic decisions and their execution. He also serves as the operating president on an interim basis when companies are going through periods of ownership succession and new management team members are being assembled.

Mr. Mizer is a former Vice President and Officer of the investment banking division of Key Capital Markets, where he focused on merger, acquisition, and financing projects for Fortune 500 clients, private companies, and successful entrepreneurs. Prior to joining Key Corp., he was Consultant in the Capital Markets practice with Ernst & Young.

He began his career as a Research Assistant with The Center for Economic Issues, a think-tank focused on economic development. He earned the B.S. (biology, applied math), B.A. (economics), M.S. degrees (biology – neurogenetics), and MBA (finance, accounting) degrees from Case Western Reserve University.

Christopher has taught business strategy, finance and entrepreneurship at the graduate level at Case Western Reserve University, John Carroll University, and the University of California, San Diego and at the undergraduate at San Diego State University.

Kenji Funahashi

Therapeutic Solutions International Spin-Off Campbell Neurosciences Recruits Global Dealmaker Kenji Funahashi to Advisory Board
https://www.prnewswire.com/news-release ... 94716.html


CNSI Business Description
https://campbellneurosciences.com/activator-of-sirt1/

Suicide is a Major Problem: In 2017, in the USA, suicide was the second leading cause of death among individuals between the ages of 10 and 34, with twice as many suicides as there were homicides[1]. Suicide is significantly more prevalent in veterans, in which approximately 20 deaths per day occur[2].

New Approaches are Needed: Psychotherapy and current drug interventions have not significantly reduced the rate of suicide. In fact, suicide rates have increased approximately 60% since 1981[3].

Suicide is not only Mental:
Suicidal ideation and suicide have been associated with inborn genetic components[4] as well as various forms of inflammation that occur as a result of brain injury[5]. In some situations, depression or other pathological mental states have been shown to induce inflammation[6], which is subsequently associated with suicidal ideation and suicide[7].

Inflammation is Major Cause of Suicide: Molecular signals which in healthy individuals are associated with the body fighting disease, such as TNF-alpha, are turned by the brain when they are needed, and turned off when the disease has been defeated. In patients with suicidal ideation, these signals are turned on at a low level without being turned off. It is known that these “inflammatory signals”, otherwise known as “inflammatory cytokines” are associated with depression based human studies in which inflammatory signals were artificially manufactured and administered in patients to fight cancer and treated patients became depressed[8]. Additionally, studies show that patients who are successfully treated for depression have a reduction in inflammatory signals in the blood[9][10]. Furthermore, various cofactors known to increase suicide rates such as drug abuse[11], alcoholism[12], and brain injury[13], have been shown to increase inflammatory signaling.

Diagnosis

Analysis of what is happening in blood. Proprietary algorithm utilizing already available blood tests to establish patients at risk of suicide (Doctor or rehab facility sends to us lab results from Quest and we plug into our computer and give risk score)
Analysis of what is happening in brain. Brain produces very small particles called exosomes that we can isolate, and they tell us how much inflammation is happening specifically in brain. Additionally, when appropriate, imaging studies using fMRI and various dyes to detect specific areas of brain atrophy and/or inflammation
Analysis of what is happening in the gut. Analysis of the microbiome in gut suggests overall inflammation in body
Analysis of suicide associated gene. Several gene polymorphisms have been shown to be associated with suicide.

The above physical findings are utilized to develop a suicide risk score, as well as to establish a baseline for intervention. In some situations physicians will only be interested in attaining our suicide risk score and they will perform their own interventions. We are the only group to have developed a suicide risk score based on medical and not psychological findings.

Intervention

Clinical trial of QuadraMune™, clinically validated to reduces biomarkers associated with suicide risk
Broad acting anti-inflammatory natural interventions. Intravenous vitamin C, vitamin D, fish oil, quercetin, micronutrients.
Specific anti-inflammatory antibodies. Anti-TNF, anti-IL-17, anti-IL21
Microbiome modulators. Probiotics, prebiotics, fecal transplants
Cell based therapies. Autologous bone marrow
Transcranial Magnetic Stimulation. Various studies have shown ability to reduce neural inflammation and augment brain regeneration using this approach.

Action Plan

Understanding intellectual property landscape around our broad ideas of diagnosis and treatment. Filing new patents and/or licensing.
Creation of a “Central Core” which analyzes data and provides patient specific recommendations together with the input from the health care professional
Collaboration with medical professionals, drug rehab clinics, etc

Resources

[1] https://www.nimh.nih.gov/health/statist ... art_154968
[2] https://www.mentalhealth.va.gov/docs/20 ... report.pdf
[3] https://webappa.cdc.gov/sasweb/ncipc/mortrate.html
[4] https://www.sciencedaily.com/releases/2 ... 113941.htm
[5] Juengst et al. Exploratory associations with tumor necrosis factor-α, disinhibition and suicidal endorsement after traumatic brain injury. Brain Behav Immun. 2014 Oct;41:134-43.
[6] Zhu et al. Neuroinflammation caused by mental stress: the effect of chronic restraint stress and acute repeated social defeat stress in mice. Neurol Res. 2019 Aug;41(8):762-769
[7] O’Donovan et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013 Apr;30(4):307-14.
[8] Illman et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol. 2005 Jan-Feb;3(1):37-50.
[9] Lanquillon et al. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000 Apr;22(4):370-9.
[10] Chen et al. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study. Psychiatry Res. 2018 Nov;269:207-211.
[11] Kapasi et al. Morphine stimulates mesangial cell TNF-alpha and nitrite production. Inflammation. 2000 Oct;24(5):463-76.
[12] Valles et al. Chronic ethanol treatment enhances inflammatory mediators and cell death in the brain and in astrocytes. Brain Pathol. 2004;14:365–371.
[13] Yang et al. Serum macrophage migration inhibitory factor concentrations correlate with prognosis of traumatic brain injury. Clin Chim Acta. 2017 Jun;469:99-104.


Campbell Score PRs / Clinical Trial

8/21/20
Therapeutic Solutions International Files Patent on Campbell Score™: The First Quantitative Tool for Assessment of Suicidal Propensity based on Immunological Markers
Ending the Stigma of Suicide

https://www.prnewswire.com/news-release ... 16310.html

10/29/20
Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score™
Clinical Stage Biotech Company Aims to Develop Biology Based Means of Assessing Suicide Risk and Providing Immunotherapy Based Interventions

https://www.prnewswire.com/news-release ... 63006.html

1/13/21
Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences
Three-Fold Increase in Inflammation Biomarker Observed in Patients with Suicidal Tendencies as Compared to Healthy Controls

https://www.prnewswire.com/news-release ... 07555.html

2/18/21
Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction
Company uses Blood Based Immune Test as "Stethoscope for the Brain"
"Suicide is a Disease, Not a Choice"

https://www.prnewswire.com/news-release ... 30996.html

Clinical Trial link :
Correlation of Campbell Score With Suicidal Ideation
https://clinicaltrials.gov/ct2/show/NCT04606875



Kaihani Score PRs / Clinical Trial

12/2/20
Therapeutic Solutions International Announces Clinical Trial Assessing "Kaihani Score" Proprietary Biomarker Based Assay for Quantifying Gambling Addiction
Clinical Stage Bionutraceutical Company Expands its Immunology Based Approach to Psychiatric Conditions

https://www.prnewswire.com/news-release ... 83823.html

2/25/21
Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Preliminary Efficacy of First Blood-Based Test for Gambling Addiction: Kaihani Score™
Suicide Prevention Company Leverages Brain-Immune Connection to Tackle 54 Billion Dollar Gambling Addiction Epidemic

https://www.prnewswire.com/news-release ... 35601.html

Clinical Trial link :
Validation of Kaihani Score for Gambling Addiction
https://www.clinicaltrials.gov/ct2/show/NCT04648007

Clinical Trial Results

4/5/21
Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Efficacy of Kaihani Score in Prediction of Gambling Addiction
Suicide Prevention Company Succeeds in Utilizing Brain-Immune Connection to Quantifiably Assess Gambling Addiction Status

https://www.prnewswire.com/news-release ... 61934.html



QuadraMune (In Re: to CNSI)

12/9/20
Therapeutic Solutions International Division of Campbell Neurosciences Files Patent on QuadraMune™ for Treatment of Major Depressive Disorder
Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac

https://www.prnewswire.com/news-release ... 89517.html

QuadraMune website :
https://quadramune.com/


QuadraMune and Minocycline


8/28/20
Therapeutic Solutions International Reports Synergistic Suppression of Suicide-Associated Neuroinflammatory Pathway by QuadraMune™ and Minocycline
Campbell Neurosciences Division Continues its Mission of "Treating Suicide as a Biological Disease"

https://www.prnewswire.com/news-release ... 20336.html



Opioid Addiction


9/24/20
Therapeutic Solutions International Announces Proof of Concept Data and Patent Filing for Neuroleukin™: The First Immune Based Suicide Prevention Biological Therapy
Campbell Neurosciences Division Continues its Aggressive "Land Grab" of Suicide Prevention Intellectual Property Space

https://www.prnewswire.com/news-release ... 37518.html

12/21/20
Therapeutic Solutions International Files Patent on NeuroLeukin™ Personalized Immunotherapy for Opioid Addiction
Campbell Neurosciences Division Expands its "Regenerative Psychiatry" Approach to Address the $179 Billion Dollar Prescription Opioid Epidemic

https://www.prnewswire.com/news-release ... 96771.html

4/13/21
Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction
Company Announces Second Therapeutic Candidate for Leveraging Regenerative and Immunological Approaches for Overcoming > $78.5 Billion Dollar Addiction Epidemic

https://www.prnewswire.com/news-release ... 67713.html

4/19/21
Therapeutic Solutions International Spin-Off Campbell Neurosciences Identifies Mechanism of Action for Umbilical Cord Blood Derived NarcoStem™ Drug Rehabilitation Product
Company Demonstrates Key Role for "Endogenous Nerve Repair Compound" in Mediating Therapeutic Activities of Novel Regenerative Approach

https://www.prnewswire.com/news-release ... 71379.html



Campbell Platform Stem Cell Therapy for Schizophrenia

9/14/20
Therapeutic Solutions International Files Comprehensive Campbell Platform™ Patent for Stem Cell Immunotherapy of Schizophrenia
Campbell Neurosciences Division Continues Groundbreaking Work Based on Treating Suicide as a Biological Disease

https://www.prnewswire.com/news-release ... 30078.html

9/28/20
Therapeutic Solutions International Reports Positive Preclinical Data on JadiCell™ Universal Donor Stem Cell Therapy for Brain Injury
FDA Cleared Stem Cell is Being Utilized by TSOI as Therapeutic Candidate to Repair Damaged Brains

https://www.prnewswire.com/news-release ... 38937.html

5/10/21
Therapeutic Solutions International Subsidiary Campbell Neurosciences Reports Positive Preclinical Data in Animal Model of Schizophrenia Using Proprietary Universal Donor Mesenchymal Stem Cell
Company Aims to Using Immunological Based Regenerative Medicine Treatment for Schizophrenic Patients Resistant to Electroconvulsive Therapy

https://www.prnewswire.com/news-release ... 87400.html

6/2/21
Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as a Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model
Company Addresses Scientific Studies as it Prepares for FDA Filing to Treat Major Cause of Suicide with Adult Stem Cells

https://www.prnewswire.com/news-release ... 03857.html

6/10/21
Therapeutic Solutions International Spinoff Campbell Neurosciences Reports Reduction of Schizophrenia Activity in Mice Subsequent to Administration of Tolerogenic Dendritic Cells
Company Continues to Advance Technologies Described in its >1000 Claim Patent on Cellular Therapy for Schizophrenia

https://www.prnewswire.com/news-release ... 09916.html

6/16/21
Campbell Neurosciences Spin Off of Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models using Low Dose Naltrexone and T Regulatory Cell Stimulation
Suicide Prevention Company Continues Experimental Validation of its >1000 Claim Patent on Application of Immunotherapy to Schizophrenia

https://www.prnewswire.com/news-release ... 13738.html




Stromal Vascular Fraction Immunotherapy / Synova Life Sciences

12/16/20
Therapeutic Solutions International Signs Letter of Intent with Premier Adipose Stem Cell Company Synova Life Sciences to File IND for Suicide Prevention
Campbell Neurosciences Division Aims to Combat Suicide-Causing Brain Inflammation using Stromal Vascular Fraction Immunotherapy

https://www.prnewswire.com/news-release ... 94504.html

Synova Life Sciences website :

https://www.synovalife.com/


Monocyte Immunotherapy for Suicide Prevention

3/4/21
Therapeutic Solutions International Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide Prevention
"First in Class" Therapy Reduces Suicide Associated Biological Pathways in Preclinical Studies

https://www.prnewswire.com/news-release ... 40517.html

Explanation:

viewtopic.php?f=2&t=544&p=3901#p3901


IL-2 Therapy for Inflammation Associated Depression

5/17/21
Therapeutic Solutions International and Campbell Neurosciences Announce Preclinical Studies Showing Low Doses of FDA Cleared Immune Stimulant Interleukin-2 Reduces Inflammation Associated Depression in Animal Model
Suicide Prevention Company Rapidly Expanding Pipeline on Immunotherapy of Psychiatric Conditions

https://www.prnewswire.com/news-release ... 92421.html
dneedle280
Posts: 20
Joined: Fri Feb 26, 2021 7:45 pm

Re: Campbell Neurosciences / CNSI - Basic Overview

Post by dneedle280 »

Any one know how and where you can purchase shares for
25 cents I'm unable to find Campbell on my trading platform.
retsehc
Posts: 27
Joined: Thu Aug 20, 2020 2:41 pm

Re: Campbell Neurosciences / CNSI - Basic Overview

Post by retsehc »

Campbell isn’t publicly traded. The $.25/share is for a private offering which is only available to accredited investors. I messaged them on Twitter regarding it and that was the response I was given.
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences / CNSI - Basic Overview

Post by trader32176 »


TSOI owns 40% of Campbell NeuroSciences / CNSI


CNSI has licensed 9 patents from TSOI @ $50K per each patent https://www.prnewswire.com/news-release ... 99636.html

https://www.sec.gov/Archives/edgar/data ... -index.htm (Exhibits 9-17)

Future sales from CNSI using TSOI products per Purchase Agreement
https://www.sec.gov/Archives/edgar/data ... ex10z7.htm
dneedle280
Posts: 20
Joined: Fri Feb 26, 2021 7:45 pm

Re: Campbell Neurosciences / CNSI - Basic Overview

Post by dneedle280 »

Thank for the info Retsehc.
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences / CNSI - Basic Overview w/ links

Post by trader32176 »

Added 5/24/21

Kenji Funahashi


Therapeutic Solutions International Spin-Off Campbell Neurosciences Recruits Global Dealmaker Kenji Funahashi to Advisory Board

https://www.prnewswire.com/news-release ... 94716.html
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences / CNSI - Basic Overview w/ links

Post by trader32176 »

Added 6/16/21 under Schizophrenia


6/16/21
Campbell Neurosciences Spin Off of Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models using Low Dose Naltrexone and T Regulatory Cell Stimulation
Suicide Prevention Company Continues Experimental Validation of its >1000 Claim Patent on Application of Immunotherapy to Schizophrenia


https://www.prnewswire.com/news-release ... 13738.html
Post Reply